SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 3

Sustained nicorandil administration reduces the infarct size in STsegment elevation myocardial infarction patients with primary percutaneous coronary intervention

Shanjie WANG
Yu DUAN
Xinyu FENG
Liang LIU
Zhaofeng SHI
Bo WANG
Chenhai XIA
Wanrong MAN
Haichang WANG
Zhijing ZHAO
Dongdong SUN
Pages
163–171
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Continuous cardioprotective therapy may be more beneficial for patients with STEMI.(Anatol J Cardiol 2019; 21: 163-71)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Currently, there is still no effective strategy to diminish the infarct size (IS) in patients with ST-segment elevation myocardial infarction (STEMI).
📊
Key Findings & Data:According to a previous animal study, nicorandil treatment is a promising pharmaceutical treatment to limit the infarct area.
💡
Conclusion & Impact:Continuous cardioprotective therapy may be more beneficial for patients with STEMI.(Anatol J Cardiol 2019; 21: 163-71)
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Currently, there is still no effective strategy to diminish the infarct size (IS) in patients with ST-segment elevation myocardial infarction (STEMI). According to a previous animal study, nicorandil treatment is a promising pharmaceutical treatment to limit the infarct area. In thisstudy, we aim to investigate the effects of continual nicorandil administration on the IS and the clinical outcomes in patients with STEMI whounderwent primary percutaneous coronary intervention (pPCI).Methods: One hundred seventeen patients with STEMI and undergoing pPCI were randomly divided into the sustained nicorandil group (5 mg,three times daily) or the control group (only single nicorandil before PCI). The primary endpoint was the IS, evaluated by single-photon emissioncomputed tomography (SPECT) 3 months after pPCI.Results: Eighty-five patients completed the IS assessment via SPECT, and 99 participants were available for follow-up after 6 months. Finally,there was a statistical difference in the IS between the nicorandil and control groups {13% [interquartile range (IQR), 8–17] versus 16% [IQR,12–20.3], p=0.027}. Additionally, we observed that maintained nicorandil administration significantly improved the left ventricular ejection fraction at 3 months and enhanced the activity tolerance (physical limitation and angina stability) at 6 months after PCI.Conclusion: Sustained nicorandil treatment reduced the IS and improved the clinical outcomes compared to the single nicorandil administrationfor patients with STEMI undergoing the pPCI procedure. Continuous cardioprotective therapy may be more beneficial for patients with STEMI.(Anatol J Cardiol 2019; 21: 163-71)

🔖

Cite This Article

WANG, S., DUAN, Y., FENG, X., LIU, L., SHI, Z., WANG, B., XIA, C., MAN, W., WANG, H., ZHAO, Z., SUN, D. (2019). Sustained nicorandil administration reduces the infarct size in STsegment elevation myocardial infarction patients with primary percutaneous coronary intervention. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 3, 163–171. https://ajindex.com/articles/365721

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dai X, Kaul P, Smith SC Jr, Stouffer GA. Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. Nat Rev Cardiol 2016; 13: 148-54
  2. Ndrepepa G. Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coron Artery Dis 2015; 26: 341-55
  3. Crea F. Coronary microvascular obstruction--a puzzle with many pieces. N Engl J Med 2015; 372: 1464-5
  4. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016; 37: 1024- 33
  5. Hausenloy DJ, Yellon DM. Targeting Myocardial Reperfusion Injury- -The Search Continues. N Engl J Med 2015; 373: 1073-5
  6. Ferreira R. The reduction of infarct size--forty years of research- -second of two parts. Rev Port Cardiol 2010; 29: 1219-44
  7. Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. JACC Cardiovasc Interv 2013; 6: 1055-63
  8. Kyhl K, Vejlstrup N, Lønborg J, Treiman M, Ahtarovski KA, Helqvist S, et al. Predictors and prognostic value of left atrial remodelling after acute myocardial infarction. Open Heart 2015; 2: e000223
  9. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011; 71: 1105-19
  10. Hirohata A, Yamamoto K, Hirose E, Kobayashi Y, Takafuji H, Sano F, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study. EuroIntervention 2014; 9: 1050-6
  11. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75
  12. Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitratelike properties in dogs. Cardiovasc Res 1996; 32: 274-85
  13. Schalla S, Higgins CB, Saeed M. Long-term oral treatment with nicorandil prevents the progression of left ventricular hypertrophy and preserves viability. J Cardiovasc Pharmacol 2005; 45: 333-40
  14. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemicreperfused rat heart. Circ J 2002; 66: